This inventor holds 1 USPTO granted patent and 3 published patent applications and 1 EPO patent. Top assignee: Merck Patent Gmbh. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Claude Gimmi-McKim: Innovator in Cancer Treatment
Introduction
Claude Gimmi-McKim is a notable inventor based in Möhlin, Switzerland. He has made significant contributions to the field of cancer treatment through his innovative research and development of pharmaceutical compounds. His work focuses on the use of pyrimidine and pyridine compounds that exhibit Bruton's tyrosine kinase (BTK) inhibitory activity.
Latest Patents
Claude Gimmi-McKim holds a patent for "Methods for treating cancer using pyrimidine and pyridine compounds with BTK inhibitory activity." This invention provides methods for treating cancer by utilizing specific compounds that inhibit BTK, which plays a crucial role in cancer cell proliferation.
Career Highlights
Claude is associated with Merck Patent GmbH, where he continues to advance his research in cancer therapies. His dedication to innovation in the pharmaceutical industry has positioned him as a key figure in the development of new treatment methodologies.
Collaborations
He has collaborated with notable colleagues, including Bayard R Huck and Samantha M Goodstal, to further enhance the impact of his research in the field of oncology.
Conclusion
Claude Gimmi-McKim's work exemplifies the importance of innovation in the fight against cancer. His contributions through patents and collaborations highlight his commitment to improving treatment options for patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile